Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 120

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson’s disease

dos Santos, Marcia Cristina T., Barreto-Sanz, Miguel Arturo, Correia, Bruna Renata S., Bell, Rosie, Widnall, Catherine, Perez, Luis Tosar, Berteau, Caroline, Schulte, Claudia, Scheller, Dieter, Berg, Daniela, Maetzler, Walter, Galante, Pedro A.F., Nogueira da Costa, Andre · 2018 · Oncotarget

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.24736

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 52

  1. Visser, 2015, Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases, Nat Rev Neurol, 11, 41, 10.1038/nrneurol.2014.232 · DOI · Paper page
  2. Lang, 2017, Parkinson disease, Nat Rev Dis Primers, 3, 17013, 10.1038/nrdp.2017.13 · DOI · Paper page
  3. Halliday, 2014, Alpha-synuclein biology in Lewy body diseases, Alzheimers Res Ther, 6, 73, 10.1186/s13195-014-0073-2 · DOI · Paper page
  4. Kulisevsky, 2012, Cognitive impairment and dementia in Parkinson’s disease, Neurobiol Dis, 46, 590, 10.1016/j.nbd.2012.03.029 · DOI · Paper page
  5. Elton, 1987, Unified Parkinson’s disease rating scale, Recent Developments in Parkinson’s Disease: Macmillan Health Care Information), 293
  6. Seitelberger, 1973, Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations, J Neurol Sci, 20, 415, 10.1016/0022-510X(73)90175-5 · DOI · Paper page
  7. Bartus, 2013, Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease, Brain, 136, 2419, 10.1093/brain/awt192 · DOI · Paper page
  8. van de Berg, 2016, Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease, Mol Neurodegener, 11, 7, 10.1186/s13024-016-0072-9 · DOI · Paper page
  9. Kotzbauer, 2015, Correlation Between Decreased CSF α-Synuclein and Aβ(1-42) in Parkinson Disease, Neurobiol Aging, 36, 476, 10.1016/j.neurobiolaging.2014.07.043 · DOI
  10. Verbeek, 2014, CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls, Parkinsonism Relat Disord, 20, 112, 10.1016/j.parkreldis.2013.09.003 · DOI
  11. Fox, 2015, Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay, Mol Neurodegener, 10, 64, 10.1186/s13024-015-0059-y · DOI · Paper page
  12. Tambasco, 2014, Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson’s disease, Mov Disord, 29, 1019, 10.1002/mds.25772 · DOI · Paper page
  13. Calabresi, 2014, Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson’s Disease, Front Aging Neurosci, 6, 53
  14. da Costa, 2016, Recent developments in circulating biomarkers in Parkinson’s disease: the potential use of miRNAs in a clinical setting, Bioanalysis, 8, 2497, 10.4155/bio-2016-0166 · DOI
  15. Bartel, 2004, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell, 116, 281, 10.1016/S0092-8674(04)00045-5 · DOI
  16. Gage, 2006, Noncoding RNAs in the mammalian central nervous system, Annu Rev Neurosci, 29, 77, 10.1146/annurev.neuro.29.051605.112839 · DOI · Paper page
  17. Lotvall, 2007, Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells, Nat Cell Biol, 9, 654, 10.1038/ncb1596 · DOI · Paper page
  18. Sonntag, 2010, MicroRNAs and deregulated gene expression networks in neurodegeneration, Brain Res, 1338, 48, 10.1016/j.brainres.2010.03.106 · DOI
  19. Dawson, 2009, Understanding microRNAs in neurodegeneration, Nat Rev Neurosci, 10, 837, 10.1038/nrn2726 · DOI · Paper page
  20. Zetterberg, 2014, Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions, J Neurol Neurosurg Psychiatry, 85, 1065, 10.1136/jnnp-2013-307539 · DOI
  21. Papavassiliou, 2013, MicroRNAs: Novel diagnostic and prognostic biomarkers in atherosclerosis, Curr Top Med Chem, 13, 1503, 10.2174/15680266113139990099 · DOI
  22. Vachev, 2015, Circulating microRNAs as a Novel Class of Potential Diagnostic Biomarkers in Neuropsychiatric Disorders, Folia Med (Plovdiv), 57, 159
  23. Hagman, 2017, Circulating microRNAs as biomarkers in progressive multiple sclerosis, Mult Scler, 23, 403, 10.1177/1352458516651141 · DOI
  24. Bahnassey, 2016, Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection, Tumour Biol, 37, 12273, 10.1007/s13277-016-5097-8 · DOI
  25. Kordower, 2015, The prion hypothesis of Parkinson’s disease, Curr Neurol Neurosci Rep, 15, 28, 10.1007/s11910-015-0549-x · DOI
  26. Franco, 2017, Metabolic Dysfunction in Parkinson’s Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism, Brain Res Bull, 133, 12, 10.1016/j.brainresbull.2017.03.009 · DOI · Paper page
  27. McLean, 2012, Protein degradation pathways in Parkinson’s disease: curse or blessing, Acta Neuropathol, 124, 153, 10.1007/s00401-012-1004-6 · DOI · Paper page
  28. Petrucelli, 2012, Disruption of protein quality control in Parkinson’s disease, Cold Spring Harb Perspect Med, 2, a009423
  29. Jozwiak, 2017, Parkin, PINK1 and DJ1 as possible modulators of mTOR pathway in ganglioglioma, Int J Neurosci, 1
  30. Luo, 2017, Deficiency in Neuronal TGF-beta Signaling Leads to Nigrostriatal Degeneration and Activation of TGF-beta Signaling Protects against MPTP Neurotoxicity in Mice, J Neurosci, 37, 4584, 10.1523/JNEUROSCI.2952-16.2017 · DOI
  31. Sipper, 2001, Fuzzy CoCo: a cooperative-coevolutionary approach to fuzzy modeling, IEEE Transactions on Fuzzy Systems, 9, 727, 10.1109/91.963759 · DOI
  32. Pena-Reyes, 2004, Evolutionary fuzzy modeling human diagnostic decisions, Ann N Y Acad Sci, 1020, 190, 10.1196/annals.1310.017 · doi:10.1196/annals.1310.017
  33. Hatzigeorgiou, 2015, DIANA-miRPath v3.0: deciphering microRNA function with experimental support, Nucleic Acids Res, 43, W460, 10.1093/nar/gkv403 · DOI · Paper page
  34. Dugger, 2014, Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study, Neurology, 83, 406, 10.1212/WNL.0000000000000641 · DOI · Paper page
  35. Lefevre, 2012, miRNA_Targets: a database for miRNA target predictions in coding and non-coding regions of mRNAs, Genomics, 100, 352, 10.1016/j.ygeno.2012.08.006 · DOI
  36. Ambros, 1993, The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14, Cell, 75, 843, 10.1016/0092-8674(93)90529-Y · DOI · Paper page
  37. Verbeek, 2016, MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson’s Disease and Multiple System Atrophy, Mol Neurobiol, 54, 7736
  38. Gibbard, 1982, The prospective Pareto Principle and equity of access to health care, Milbank Mem Fund Q Health Soc, 60, 399, 10.2307/3349800 · doi:10.2307/3349800
  39. Alvarez, 2013, Profile of microRNAs in the plasma of Parkinson’s disease patients and healthy controls, J Neurol, 260, 1420, 10.1007/s00415-013-6900-8 · DOI
  40. Lu, 2010, Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression, Nature, 466, 637, 10.1038/nature09191 · DOI · Paper page
  41. Jeromin, 2014, CSF alpha-synuclein and UCH-L1 levels in Parkinson’s disease and atypical parkinsonian disorders, Parkinsonism Relat Disord, 20, 382, 10.1016/j.parkreldis.2014.01.011 · DOI
  42. Hansson, 2015, CSF biomarkers and clinical progression of Parkinson disease, Neurology, 84, 57, 10.1212/WNL.0000000000001098 · DOI · Paper page
  43. Fernandez, 2015, Correlates of cerebrospinal fluid levels of oligomeric- and total-alpha-synuclein in premotor, motor and dementia stages of Parkinson’s disease, J Neurol, 262, 294, 10.1007/s00415-014-7560-z · DOI
  44. Lees, 1992, Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases, J Neurol Neurosurg Psychiatry, 55, 181, 10.1136/jnnp.55.3.181 · DOI · Paper page
  45. Seidl, 2004, Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations, Mov Disord, 19, 1020, 10.1002/mds.20213 · DOI · Paper page
  46. Feng, 2016, Resting-state functional connectivity of subthalamic nucleus in different Parkinson’s disease phenotypes, J Neurol Sci, 371, 137, 10.1016/j.jns.2016.10.035 · DOI
  47. Mir, 2017, Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson’s disease subtype, PLoS One, 12, e0174644, 10.1371/journal.pone.0174644 · doi:10.1371/journal.pone.0174644
  48. Wiltfang, 2006, The German Competence Net Dementias: standard operating procedures for the neurochemical dementia diagnostics, J Neural Transm (Vienna), 113, 1075, 10.1007/s00702-006-0511-9 · DOI
  49. Salzberg, 2009, Ultrafast and memory-efficient alignment of short DNA sequences to the human genome, Genome Biol, 10, R25, 10.1186/gb-2009-10-3-r25 · DOI · Paper page
  50. Haussler, 2002, The human genome browser at UCSC, Genome Res, 12, 996, 10.1101/gr.229102 · DOI · Paper page
  51. Hourlier, 2016, Ensembl 2016, Nucleic Acids Res, 44, D710, 10.1093/nar/gkv1157 · DOI · Paper page
  52. Jian, 2016, miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database, Nucleic Acids Res, 44, D239, 10.1093/nar/gkv1258 · DOI · Paper page

Cited by

Metadata

Authors
dos Santos, M. C. T., Barreto-Sanz, M. A., Correia, B. R. S., Bell, R., Widnall, C., Perez, L. T., Berteau, C., Schulte, C., Scheller, D., Berg, D., Maetzler, W., Galante, P. A. F., & Nogueira da Costa, A.
Affiliations
  • Experimental Medicine and Diagnostics, Global Exploratory Development, UCB Biopharma SPRL, Braine-l'Alleud, Belgium
  • SimplicityBio SA, Monthey, Switzerland
  • Hospital Sirio Libanes, São Paulo, Brazil
  • Centre for Misfolding Diseases, University of Cambridge, Cambridge, UK
  • Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK
  • Bioanalytical Sciences, Non Clinical Development, UCB Biopharma SPRL, Belgium
  • Hertie Institute for Clinical Brain Research, Department of Neurodegeneration, University of Tuebingen and German Center for Neurodegenerative Diseases, Tuebingen, Germany
  • Consultancy Neuropharm, Neukirchener, Neuss, Germany
Venue
Oncotarget
Published
2018-04-03
Volume
9
Issue
25
Pages
17455-17465
ISSN
1949-2553
Cited by
120
References
9
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.